When combined with anti-CTLA-4 checkpoint blockade, the therapy produced synergistic tumor regression, demonstrating how VSV’s innate immune activation can be leveraged to boost the efficacy of ICIs. This evidence concerns the gene CTLA4 and neoplasm.